Reticulocyte production index as a predictor of clinically significant anemia in chronic hepatitis C patients receiving pegylated interferon combination therapy

ADVANCES IN DIGESTIVE MEDICINE - Tập 3 - Trang 18-23 - 2016
Sheng-Lei Yan1, Cheng-Shyong Chang2, Chien-Hua Chen1,3, Yung-Hsiang Yeh1,3, Chien-Yu Tsai2
1Division of Gastroenterology, Department of Internal Medicine, Chang Bing Show-Chwan Memorial Hospital, Changhua County 505, Taiwan
2Division of Hemato-Oncology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
3Division of Gastroenterology, Department of Internal Medicine, Show-Chwan Memorial Hospital, Changhua, Taiwan

Tóm tắt

SummaryBackgroundThis work was conducted to study the relationship of reticulocyte production index to clinically significant anemia in chronic hepatitis C patients receiving pegylated interferon combination therapy.MethodsA total of 69 chronic hepatitis C patients receiving pegylated interferon combination therapy were included. Clinically significant anemia was defined as a hemoglobin level of < 10 g/dL. Reticulocyte count values were determined at the baseline and during treatment (4 weeks, 12 weeks, and 24 weeks). Reticulocyte production indices were calculated according to formulae. Clinical variables were analyzed using univariate analysis. Variables that were found to be significant on univariate analysis were included in multivariate analysis. A p value < 0.05 was regarded as statistically significant.ResultsClinically significant anemia was observed in 30 patients (43.5%), and 39 patients (56.5%) never developed clinically significant anemia during the whole treatment course. On multivariate analysis, age > 60 years [odds ratio (OR), 2.94; 95% confidence interval (CI), 1.09–7.93], pretreatment hemoglobin level < 14 g/dL (OR, 5.76; 95% CI, 2.01–16.48), and reticulocyte production index < 0.9% (OR, 5.50; 95% CI, 1.78–16.97) at Week 4 were significantly associated with clinically significant anemia.ConclusionBesides old age and low pretreatment hemoglobin level, our study showed that a reticulocyte production index < 0.9% at Week 4 was a significant factor associated with clinically significant anemia during pegylated interferon combination treatment.

Tài liệu tham khảo

10.1016/S0140-6736(01)06102-5 10.1056/NEJMoa020047 10.1111/j.1572-0241.2007.01139.x 10.1002/hep.510260231 10.1111/j.1478-3231.2006.01228.x Adamson J.W., 2008, Harrison's principles of internal medicine, 358 2001, Rebetron® combination therapy containing Rebetol® (ribavirin, USP) capsules and Intron® A (interferon alpha‐2b, recombinant) injection prescribing information 10.1007/s00535-003-1363-9 10.1111/j.1440-1746.2004.03459.x 10.1111/j.1365-2893.2004.00490.x VanVlierberghe H., 2001, BASL Steering Committee. Factors influencing ribavirin‐induced hemolysis, J Hepatol, 34, 911, 10.1016/S0168-8278(01)00029-0 10.1111/j.1572-0241.2008.01957.x 10.1007/s00535-006-1858-2 10.1111/j.1872-034X.2007.00205.x 10.1007/s00535-011-0412-z 10.3109/0886022X.2011.650562 10.1111/j.1572-0241.2005.40757.x
Thông tin
Thông tin xuất bản

ADVANCES IN DIGESTIVE MEDICINE

Tập 3

18-23

Thông tin tác giả